The Latest Breaking News from MarketBeat

Alphabet’s Waymo and Services Beginning to Feel the Pressure?

Waymo remains a significant long-term opportunity for Alphabet, but profitability, competition, and regulatory challenges persist.

MarketBeat · Jun 30, 2025

S&P 500 All-Time Highs: 5 Catalysts Driving It Higher

The S&P 500 is expected to continue rising in 2025, as leading stocks are at or on the cusp of new highs, driven by bullish fundamentals and catalysts.

MarketBeat · Jun 30, 2025

3 Dividend Kings Trading at Rare Discounts to Buy This Summer

Here are 3 Dividend Kings (HRL, GPC, PG) currently trading near long-term lows, offering attractive yields and growth potential, to buy this summer.

MarketBeat · Jun 30, 2025

AutoNation: Growth Engines Make It an Undervalued Stock

AutoNation’s value lies in its high-margin service and finance divisions, a fundamental strength that suggests its current stock price is undervalued.

MarketBeat · Jun 29, 2025

Snowflake Hits 52-Week High—Options Traders Bet on Further Rally

A new wave of call option traders have found a reason to place a big bet that Snowflake stock may be pushing for higher prices in the near future.

MarketBeat · Jun 29, 2025

3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value

MarketBeat · Jun 29, 2025

Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making?

Apple has been a dud in 2025. But, the firms dominance in the device market gives it time to catch up and cash in on a world of AI opportunity long-term.

MarketBeat · Jun 28, 2025

Value Alert: 3 High-Yield Stocks Trading at 52-Week Lows

Stocks trading near their 52-week lows offer opportunity and higher yields but come with risk. The question is if these three stocks are a buy, sell, or hold?

MarketBeat · Jun 28, 2025

Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.

MarketBeat · Jun 28, 2025

Stable Yield & Growth: Duke Energy Upgraded to Buy by Goldman

A leading firm’s recent upgrade of Duke Energy highlights the utility's massive growth plan and its potential as a leader in a defensive market rotation.

MarketBeat · Jun 28, 2025